Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DNA Vaccine with Electroporation in HIV-Infected Adults
NCT03606213Phase 2Completed
- Start
- Aug 2018
- Primary completion
- May 2021
- Modality
- Prophylactic Vaccines, DNA Vaccines
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of PENNVAX-GP in human immunodeficiency virus type 1 infection (HIV-1) (4 arms). Primary endpoints: Percentage of Participants With Grade 3 or Higher Treatment-related Adverse Events at Week 64 and Change in the Magnitude of T Cell Responses Evaluated by IFN-gamma ELISpot at Week 14. Started Aug 2018; status: completed.
02
Drugs
PENNVAX-GP
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT03606213.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03606213.